One of the first projects on our DCTMS platform, the AcT trial is a Pragmatic Phase III randomized open-label registry-based trial with blinded end-point assessment. The trial seeks to test whether intravenous tenecteplase (an intravenous thrombolytic drug tested and found safe in multiple phase 2 and one phase 3 trial is patients with acute ischemic stroke) can replace intravenous alteplase (the current standard care) in patients who are otherwise eligible to receive the latter in routine care.
ACT-QUICR is a custom designed Electronic Data Capture (EDC) and Randomization Solution with the purpose of facilitating the data collection for the ACT-QUICR trial, while providing the following functions:
At heart, we are a dynamic and open-minded group of individuals that want to help companies succeed. First and foremost, we are critical thinkers and problem solvers.Contact Us